Although these increases in CV markers suggest that the use of GLP-1 RA may induce weight loss while also improving CV outcomes, trials specifically designed to investigate CV outcomes in patients with diabetes and obesity have yet to be completed. Here, GLP1R is linked to obesity disorder.